Aarey Drugs & Pharma: Certificate under SEBI Depositories Regs for Q1 FY27
Aarey Drugs & Pharmaceuticals Limited received a certificate for the quarter ended June 30, 2026, under SEBI (Depositories and Participants) Regulations, 2018. The Registrar and Share Transfer Agent confirmed the processing of dematerialised securities.
This is a standard compliance filing related to share dematerialisation, which is a routine process for listed companies and typically has no direct impact on the company's operations or stock price.
The announcement is a routine regulatory filing and does not contain any material financial information or operational updates that would suggest a positive or negative sentiment.
Aarey Drugs & Pharmaceuticals Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended June 30, 2026.
The certificate was received from M/s. MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent. It confirms that securities received from depository participants for dematerialisation during the specified quarter were processed and confirmed with the depositories. The security certificates received for dematerialisation have been mutilated and cancelled after verification, and the depositories have been substituted as the registered owners within the prescribed timelines.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.